About our partners
The CRC for Chronic Inflammatory Diseases has one core commercial partner:
 As one of the world’s leading pharmaceutical companies, AstraZeneca is committed to working with our CRC to find new targets for therapies for rheumatoid arthritis and chronic obstructive pulmonary (lung) disease. AZ provide medicines designed to fight a range of diseases in important areas of medical need, including inflammatory diseases like RA, cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory illnesses. AstraZeneca’s products are available in more than 100 countries and they spend over $15 million every working day on the research and development of new medicines. As our core commercial partner, AstraZeneca has specific rights to intellectual property developed from our research. AZ see the CRC for Chronic Inflammatory Diseases as a good strategic fit with their business needs. This is because the CRC for CID:
- Focuses on rheumatology and respiratory disease
- Focuses on new targets in diseases of highest strategic importance to AZ eg: chronic obstructive pulmonary disease
- Has world class scientists.
- Has centres of excellence in macrophage biology
More information about AZ
The CRC has one supporting commercial partner:
 Zimmer Inc
Zimmer is the world leader in orthopaedics and works with our CRC on Research Program 4 into joint prostheses. Zimmer has rights to specified intellectual property developed from this research. Zimmer has almost 6,500 staff around the world and their hip and knee joint replacement systems and related products and services are used by health care providers in more than 60 countries.
Zimmer’s partnership with our CRC only began in late 2003 and is already progressing very fruitfully.
More information about Zimmer
| 
